Hikma Pharmaceuticals Plc retained earnings (accumulated deficit) for the quarter ending December 31, 2023 were $2.158B, a 14.06% increase year-over-year.
Hikma Pharmaceuticals Plc retained earnings (accumulated deficit) for 2023 were $2.158B, a 3.15% increase from 2022.
Hikma Pharmaceuticals Plc retained earnings (accumulated deficit) for 2022 were $2.092B, a 4.43% decline from 2021.
Hikma Pharmaceuticals Plc retained earnings (accumulated deficit) for 2021 were $2.189B, a 15.7% increase from 2020.